13F reference period
Q3 2026
Security Snapshot
Zura Bio Ltd - Class A Ordinary Shares, par value $0.0001 per share (ZURA) Institutional Ownership
CUSIP: G9TY5A101
13F Institutional Holders and Ownership History from Q1 2023 to Q3 2026
Institutions Reporting
50
Shares (Excl. Options)
11.19M
Full value: 11,187,513 · shares · 30 Sep 2026Price
$4.16
The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Class A Ordinary Shares, par value $0.0001 per share
- Symbol
- ZURA on Nasdaq
- All holders as of 30 Sep 2026
- Q3 2026
- Total 13F shares
- 11,187,513
- Total 13F value
- $46,467,617
- Portfolio coverage rank
- 0%
- Share change
- -458,117
- Value change
- -$1,962,164
- Number of holders
- 50
- Shares outstanding
- 99,155,394
- SEC-reported price per share
- $4.00
- Insider filing price
- $4.00
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- ZURA - Zura Bio Ltd - Class A Ordinary Shares, par value $0.0001 per share is tracked under CUSIP G9TY5A101.
- 50 institutions reported positions in Q3 2026.
- 10 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 95 to 50 between Q2 2026 and Q3 2026.
- SEC-reported value moved from to
$428.85M
Full value: $428,852,480 · USD · 30 Jun 2026.$46.47M
Full value: $46,467,617 · USD · 30 Sep 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 50 institutions filings for Q3 2026.
Security key
G9TY5A101
13F reference period
Q3 2026
13F holders
50
13D/G owners
10
CIK / CUSIP context first
Open Q3 2026 holders
ZURA full holder history
Zura Bio Ltd SEC filings
Zura Bio Ltd company facts
Zura Bio Ltd insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP G9TY5A101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
10
Security
ZURA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| AI Biotechnology LLC | 18% | -8.5% | $103,223,132 | +$28,154,420 | 19,699,071 | +38% | AI Biotechnology LLC | 26 Feb 2026 |
| Athanor Capital | 16% | 0% | $60,678,440 | 11,581,402 | 0% | Athanor Capital | 23 Jan 2026 | |
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | 0% | $59,192,796 | +$20,882,077 | 9,816,384 | +55% | Venrock Healthcare Capital Partners III, L.P. | 31 Mar 2026 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 9.9% | +14% | $57,431,306 | +$23,862,290 | 9,524,263 | +71% | Suvretta Capital Management, LLC | 31 Mar 2026 |
| JPMORGAN CHASE & CO | 4.7% | -35% | $26,962,035 | -$1,212,633 | 4,471,316 | -4.3% | JPMORGAN CHASE & CO | 30 Apr 2026 |
| GREAT POINT PARTNERS LLC | 4.4% | -15% | $25,422,058 | +$2,412,000 | 4,215,930 | +10% | Great Point Partners, LLC | 31 Mar 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 4.9% | $4,633,204 | 3,217,503 | RA Capital Management, L.P. | 31 Dec 2024 | |||
| PFIZER INC | 4.6% | $4,276,832 | 2,970,022 | Pfizer Inc. 13-5315170 | 31 Dec 2024 | |||
| ADAR1 Capital Management, LLC | 3.2% | $2,991,241 | 2,077,251 | ADAR1 Capital Management, LLC | 31 Dec 2024 | |||
| Deep Track Capital, LP | 0.4% | -96% | $1,121,531 | -$18,867,975 | 259,014 | -94% | Deep Track Capital, LP | 30 Sep 2025 |
As of 30 Sep 2026,
50
institutional investors reported holding
shares of
Zura Bio Ltd - Class A Ordinary Shares, par value $0.0001 per share (ZURA).
This represents
11%
of the company’s total
outstanding shares.
11.19M
Full value: 11,187,513 · shares · 30 Sep 202699.16M
Full value: 99,155,394 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
11%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Siren, L.L.C. | 3.8% | 3,734,866 | 0% | 0.37% | $15,537,043 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.5% | 1,504,890 | -5% | 0% | $6,261,915 |
| STATE STREET CORP | 1.3% | 1,288,605 | +29% | 0% | $5,360,597 |
| Affinity Asset Advisors, LLC | 0.81% | 800,000 | -45% | 0.19% | $3,328,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | 0.7% | 696,608 | -6.8% | 0% | $2,897,889 |
| Pfizer Inc | 0.54% | 538,841 | 0% | 1.3% | $2,176,918 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.54% | 536,951 | +32% | 0% | $2,233,716 |
| Qube Research & Technologies Ltd | 0.46% | 452,835 | 0% | $1,883,794 | |
| VANGUARD FIDUCIARY TRUST CO | 0.4% | 393,223 | -3.3% | 0% | $1,635,808 |
| Alberta Investment Management Corp | 0.13% | 133,200 | 0% | 0% | $554,112 |
| ALPS ADVISORS INC | 0.13% | 126,053 | +31% | 0% | $524,380 |
| DIMENSIONAL FUND ADVISORS LP | 0.11% | 106,458 | +93% | 0% | $441,719 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 0.1% | 100,000 | 0.05% | $416,000 | |
| MORGAN STANLEY | 0.08% | 81,077 | -84% | 0% | $337,280 |
| RBF Capital, LLC | 0.06% | 58,193 | 0% | 0.01% | $242,083 |
| AMERICAN CENTURY COMPANIES INC | 0.06% | 55,385 | +37% | 0% | $230,402 |
| DEUTSCHE BANK AG\ | 0.05% | 52,871 | -9.9% | 0% | $219,944 |
| RENAISSANCE TECHNOLOGIES LLC | 0.05% | 50,700 | -84% | 0% | $210,912 |
| HERITAGE OAK WEALTH ADVISORS LLC | 0.05% | 46,000 | 0.06% | $191,360 | |
| Jump Financial, LLC | 0.04% | 43,883 | -81% | 0% | $182,553 |
| Y-Intercept (Hong Kong) Ltd | 0.04% | 38,448 | 0% | $159,944 | |
| LOS ANGELES CAPITAL MANAGEMENT LLC | 0.03% | 33,424 | +98% | 0% | $139,044 |
| Invesco Ltd. | 0.03% | 31,084 | -3% | 0% | $129,309 |
| Creative Planning | 0.03% | 29,608 | 0% | $123,169 | |
| RAYMOND JAMES FINANCIAL INC | 0.03% | 28,490 | -1.1% | 0% | $118,519 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
15
Headline period
Q3 2026
Rows shown
1-15 of 15
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 11,187,513 | $46,467,617 | -$1,962,164 | $4.16 | 50 |
| 2026 Q2 | 72,935,669 | $428,852,480 | +$41,318,368 | $5.90 | 95 |
| 2026 Q1 | 66,058,173 | $391,774,465 | +$125,573,004 | $5.95 | 94 |
| 2025 Q4 | 44,873,374 | $235,135,504 | +$20,832,407 | $5.24 | 74 |
| 2025 Q3 | 41,126,986 | $178,078,060 | +$26,729,478 | $4.33 | 65 |
| 2025 Q2 | 35,347,572 | $37,112,793 | -$12,588,212 | $1.05 | 62 |
| 2025 Q1 | 45,725,666 | $58,985,346 | +$1,915,127 | $1.29 | 74 |
| 2024 Q4 | 42,890,401 | $107,244,382 | -$472,426 | $2.50 | 87 |
| 2024 Q3 | 37,204,097 | $151,039,161 | +$13,196,426 | $4.06 | 77 |
| 2024 Q2 | 32,818,331 | $114,851,034 | +$63,732,200 | $3.50 | 55 |
| 2024 Q1 | 14,795,561 | $37,551,435 | -$1,318,315 | $2.57 | 43 |
| 2023 Q4 | 15,148,165 | $70,695,884 | +$2,995,975 | $4.67 | 43 |
| 2023 Q3 | 14,140,309 | $93,326,247 | +$8,351,323 | $6.60 | 41 |
| 2023 Q2 | 12,843,918 | $105,028,129 | +$104,999,517 | $8.20 | 38 |
| 2023 Q1 | 25,742 | $24,692 | +$24,692 | $10.00 | 3 |